Destiny Pharma PLC is a United Kingdom-based clinical stage biotechnology company. The Company is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. The exeporfinium chloride (XF) Drug series is the Companyâ€™s anti-microbial drug platform and comprises the related XF and drugs described by Destiny Pharma (DPD) drug candidate. Its pipeline for the XF Drug products includes XF-73 Nasal, XF-73 Throat, XF-70 Dermal and XF-70 Lung. XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 is in the clinical development stage for the prevention of post-surgical staphylococcal infections. XF-73 has completed four Phase I /II A studies in Europe.